Principal Investigator
Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT03692065
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Mara Westendorp, Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT03692065
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Mara Westendorp, Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
